Cartilage Injury Clinical Trial
Official title:
A Prospective, Multi-Center Study Evaluating ProChondrix® CR for the Repair of Focal Articular Cartilage Defects in the Knee
Verified date | May 2024 |
Source | AlloSource |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of this clinical study is to evaluate the use of ProChondrix Cryopreserved Osteochondral Allograft to obtain evidence of effectiveness, defined as an improvement in physical function and pain, when used on a symptomatic cartilage defect on the femoral condyle or patella in a mechanically stable knee.
Status | Active, not recruiting |
Enrollment | 34 |
Est. completion date | December 30, 2026 |
Est. primary completion date | April 1, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: - Patient is =18 and = 60 years old at the time of surgery; - Symptomatic patient presenting with moderate to severe pain in the index knee - unresponsive to conservative treatment (i.e. medication, bracing, physical therapy) and/or previous surgical intervention; - Radiographically diagnosed, by MRI, or through arthroscopy, to have a cartilage defect on the femoral condyle or patella between = 1 cm2 and = 5 cm2, measured as a rectangle length x width; - Will be having a marrow stimulation plus ProChondrix CR procedure; - Has an intact meniscus (maximum of =50% resected); - Have the ability to understand the requirements of the study, to provide written informed consent, and to comply with the study protocol. Exclusion Criteria: - Has > 5° of varus or valgus deformity; - Bipolar articular cartilage involvement (kissing lesions) of the ipsilateral compartment (i.e. > than ICRS Grade 2 on the opposing articular surface); - Associated damage to the underlying subchondral bone >2 mm requiring osseous repair; - Requires concomitant ligament repair other than Anterior Cruciate Ligament (ACL) or Medial Patella-Femoral Ligament (MPFL) reconstruction; - Body Mass Index (BMI)of = 35 kg/m2; - Active malignancy: undergoing treatment for tumor or boney traumatic injury or a history of any invasive malignancy (except non-melanoma skin cancer), unless the patient has been treated with curative intent and there have been no clinical signs or symptoms of the malignancy for at least 5 years; - Clinical and/or radiographic disease in the affected joint that includes: osteoarthritis or avascular necrosis, gout or a history of gout or pseudogout, osteochondritis dissecans with significant bone loss; - Cartilage lesion location such that the implanted graft will not be adequately shouldered; - Active local microbial infection or a systemic infection, including prior or pending treatment for HIV, syphilis, Hepatitis B or Hepatitis C; - Currently immunologically suppressed or immunocompromised, or a medical condition requiring radiation, chemotherapy or immunosuppression; - Unstable cardiovascular, renal, hepatic, endocrine and/or pulmonary disease, cancer or uncontrolled diabetes; - Has a history of any inflammatory or connective tissue disease, such as, systemic lupus erythematosus (SLE), Addison's disease, Crohn's disease, multiple sclerosis, polychondritis or rheumatoid arthritis; - Received hyaluronic acid injections into the joint space = 90 days prior to surgery; - Is a female patient who is pregnant; - Physically or mentally compromised (i.e. being currently treated for a psychiatric disorder, senile dementia, Alzheimer's disease) in a manner that would compromise his/her ability to participate in the clinical study; - Has a history of substance abuse (recreational drugs, alcohol) or has been treated in the last 6 months before enrollment for alcohol and/or drug abuse in an in-patient substance abuse program; - Patients who, in the opinion of the Investigator, would not be able or willing to comply with the protocol; - Is currently involved in a study of another investigational product for similar purpose or has been in the previous 90 days; - Has any contraindications for MRI; - Is a ward of the state, prisoner, or transient. |
Country | Name | City | State |
---|---|---|---|
United States | Midwest Orthopaedics at Rush | Chicago | Illinois |
United States | Beacon Orthopaedics & Sports Medicine | Cincinnati | Ohio |
United States | University of Kentucky Research Foundation | Lexington | Kentucky |
Lead Sponsor | Collaborator |
---|---|
AlloSource |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Subjective International Knee Documentation Committee (IKDC) Score | Change in physical pain and function as assessed by IKDC score from baseline to 60 months post-surgery | Baseline, 3, 6, 12, 24, 36, 48 and 60 months | |
Secondary | Knee injury and Osteoarthritis Outcome Score (KOOS) | Change of physical pain as assessed by KOOS score from baseline to 60 months post-surgery | Baseline, 3, 6, 12, 24, 36, 48 and 60 months | |
Secondary | SF-12 survey | Change in functional health and well-being as assessed by SF-12 survey from baseline to 60 months post-surgery | Baseline, 3, 6, 12, 24, 36, 48 and 60 months | |
Secondary | Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) Scores | Assessment of repair cartilage structure | 12, 24 and 60 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03479775 -
Muscle Function and Traumatic Knee Injury in Sports
|
||
Recruiting |
NCT03321812 -
Clinical Study of Decalcification Bone Scaffold for Cartilage Lesions of the Knee
|
N/A | |
Recruiting |
NCT06082531 -
Effect of Platelet-rich Plasma (PRP) Injection on Knee Osteoarthritis
|
N/A | |
Completed |
NCT06078072 -
Biomaterials and Mesenchymal Stem/Stromal Cells in the Treatment of Knee Articular Surface Lesions
|
||
Completed |
NCT04889443 -
Spontaneous Healing of ARticular Cartilage (SHARC)
|
||
Completed |
NCT04118023 -
7T MRI to Evaluate Cartilage Defects in the Knee
|
||
Active, not recruiting |
NCT01458782 -
ACI-C Versus AMIC. A Randomized Trial Comparing Two Methods for Repair of Cartilage Defects in the Knee
|
N/A | |
Recruiting |
NCT03477942 -
Impact of Mesenchymal Stem Cells in Knee Osteoarthritis
|
Phase 1 | |
Completed |
NCT01473199 -
BioPoly RS Knee Registry Study for Cartilage Defect Replacement
|
N/A | |
Recruiting |
NCT05124613 -
The Impact of Covid-19 on Patients Waiting for Knee Surgery
|
||
Recruiting |
NCT06344481 -
The Hyalex First-in-Human Study
|
Phase 1 | |
Completed |
NCT04739930 -
Autologous Bone Marrow Concentrate in Knee Osteochondral Allograft Transplantation
|
N/A | |
Recruiting |
NCT05328674 -
Clinical and Comparative Evaluation of the Treatment Results of Arthroscopic Reconstruction of Cartilage Defects in the Knee Joint With the Use of Autogenous Cartilage Graft With PRP GF (Platelet-rich Plasma With Growth Factors)
|
N/A | |
Recruiting |
NCT04184687 -
The Treatment of Cartilaginous Lesions and Concomitant Anterior Cruciate Ligament Reconstruction
|
N/A | |
Terminated |
NCT04301258 -
ProChondrix® CR Articular Cartilage Restoration Evaluation (PACE) Registry
|
||
Completed |
NCT02696876 -
Synovium Brushing to Augmented Microfracture for Improved Cartilage Repair
|
N/A | |
Completed |
NCT02637505 -
Norwegian Cartilage Project - Microfracture
|
N/A | |
Recruiting |
NCT04135950 -
Prospective Registry of Anterior Cruciate Ligament Reconstructions
|
||
Completed |
NCT03024801 -
Effectiveness of Autologous Platelet-rich Plasma on Knee Cartilage Injury
|
N/A | |
Completed |
NCT01041001 -
Study to Compare Efficacy and Safety of Cartistem and Microfracture in Patients With Knee Articular Cartilage Injury
|
Phase 3 |